These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35096992)

  • 1. Myocardial PD-L1 Expression in Patients With Ischemic and Non-ischemic Heart Failure.
    Kushnareva E; Kushnarev V; Artemyeva A; Mitrofanova L; Moiseeva O
    Front Cardiovasc Med; 2021; 8():759972. PubMed ID: 35096992
    [No Abstract]   [Full Text] [Related]  

  • 2. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 EXPRESSION IN NORMAL ENDOCRINE TISSUES IS NOT INCREASED DESPITE HIGH INCIDENCE OF PD-1 INHIBITOR-ASSOCIATED ENDOCRINOPATHIES.
    Pollack R; Kagan M; Dresner-Pollak R; Neuman T
    Endocr Pract; 2021 Jan; 27(1):34-37. PubMed ID: 33475499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of immune checkpoint inhibitors.
    Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
    ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of
    Krawczyk P; Jarosz B; Kucharczyk T; Grenda A; Reszka K; Pankowski J; Wojas-Krawczyk K; Nicoś M; Szumiło J; Trojanowski T; Milanowski J
    Oncotarget; 2017 Sep; 8(38):64283-64293. PubMed ID: 28969070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Multiple Causes of Cardiac Death After the First Infusion of Atezolizumab: Histopathological and Immunohistochemical Findings.
    Kushnareva E; Stepanova M; Artemeva E; Shuginova T; Kushnarev V; Simakova M; Moiseenko F; Moiseeva O
    Front Immunol; 2022; 13():871542. PubMed ID: 35432332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of immunohistochemical conditions on the results of PD-L1 (22C3) staining].
    Luo XL; Luo LQ; He J; Liao JQ; Liu C; Liu YH; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1108-1113. PubMed ID: 33152813
    [No Abstract]   [Full Text] [Related]  

  • 12. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiotoxicity of Anti-PD-L1 Antibody and the Effect of Levothyroxine 
in Attenuating the Related Mortality in Mice].
    Chen Z; Wang M; Gao S; Guo H; Wang G; Zhou G
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):394-403. PubMed ID: 34157799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
    Neuman T; London M; Kania-Almog J; Litvin A; Zohar Y; Fridel L; Sandbank J; Barshak I; Vainer GW
    J Thorac Oncol; 2016 Nov; 11(11):1863-1868. PubMed ID: 27664534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
    Passiglia F; Bronte G; Bazan V; Natoli C; Rizzo S; Galvano A; Listì A; Cicero G; Rolfo C; Santini D; Russo A
    Oncotarget; 2016 Apr; 7(15):19738-47. PubMed ID: 26918451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.
    Gabrych A; Pęksa R; Kunc M; Krawczyk M; Izycka-Swieszewska E; Biernat W; Bień E
    Pathol Res Pract; 2019 Dec; 215(12):152700. PubMed ID: 31704149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
    Yuan P; Guo CY; Li Y; Jiang LL; Liu YP; Liu XY; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):840-844. PubMed ID: 30423607
    [No Abstract]   [Full Text] [Related]  

  • 19. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
    Karatrasoglou EA; Chatziandreou I; Sakellariou S; Stamopoulos K; Kavantzas N; Lazaris AC; Korkolopoulou P; Saetta AA
    Virchows Arch; 2020 Aug; 477(2):207-217. PubMed ID: 31989260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.